{"id":9638,"date":"2021-05-06T17:01:40","date_gmt":"2021-05-07T00:01:40","guid":{"rendered":"https:\/\/depts.washington.edu\/pandemicalliance\/?p=9638"},"modified":"2021-05-07T17:02:22","modified_gmt":"2021-05-08T00:02:22","slug":"efficacy-of-nvx-cov2373-covid-19-vaccine-against-the-b-1-351-variant","status":"publish","type":"post","link":"https:\/\/depts.washington.edu\/pandemicalliance\/2021\/05\/06\/efficacy-of-nvx-cov2373-covid-19-vaccine-against-the-b-1-351-variant\/","title":{"rendered":"Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant"},"content":{"rendered":"<ul>\n<li style=\"font-weight: 400\"><span style=\"font-weight: 400\">Results from a multicenter, randomized, observer-blinded, placebo-controlled phase 2a-b trial in South Africa of the NVX-CoV2373 (Novavax) nanoparticle vaccine indicated a 49% vaccine efficacy against SARS-CoV-2 infection among 2,684 participants. 94% of participants were HIV-negative and 6% were people living with HIV. After 1:1 vaccine to placebo randomization, 15 participants in the vaccine arm and 29 participants in the placebo arm developed predominantly mild to moderate COVID-19. Efficacy in HIV-negative participants was 60% and did not differ by presence of antibodies at baseline.\u00a0 Among individuals who developed COVID-19 and had a sequenced viral isolate, 38 (93%) of 41 were the B.1.351 variant and post-hoc vaccine efficacy against B.1.351 was 51% among the HIV-negative participants.<\/span><\/li>\n<li style=\"font-weight: 400\"><span style=\"font-weight: 400\">Notably, among placebo recipients the incidence of symptomatic COVID-19 was similar in those with and without evidence of anti-SARS-CoV-2 antibodies at baseline during the first 2 months of follow-up (5.3% vs 5.2%).\u00a0 The authors conclude that this suggests prior infection provided no protection against developing clinical disease when infected with the B.1.351 variant. <\/span><i><span style=\"font-weight: 400\">[EDITORIAL NOTE: An earlier version of this manuscript was summarized as a pre-print in the report on March 3, 2021].<\/span><\/i><\/li>\n<\/ul>\n<p><i><span style=\"font-weight: 400\">Shinde et al.\u00a0(May 5, 2021). Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant. New England Journal of Medicine. <\/span><\/i><a href=\"https:\/\/doi.org\/10.1056\/NEJMoa2103055\"><span style=\"font-weight: 400\">https:\/\/doi.org\/10.1056\/NEJMoa2103055<\/span><\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Results from a multicenter, randomized, observer-blinded, placebo-controlled phase 2a-b trial in South Africa of the NVX-CoV2373 (Novavax) nanoparticle vaccine indicated a 49% vaccine efficacy against SARS-CoV-2 infection among 2,684 participants. 94% of participants were HIV-negative and 6% were people living with HIV. After 1:1 vaccine to placebo randomization, 15 participants in the vaccine arm and&#8230;<\/p>\n<div><a class=\"more\" href=\"https:\/\/depts.washington.edu\/pandemicalliance\/2021\/05\/06\/efficacy-of-nvx-cov2373-covid-19-vaccine-against-the-b-1-351-variant\/\">Read more<\/a><\/div>\n","protected":false},"author":8,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_links_to":"","_links_to_target":""},"categories":[6],"tags":[33],"topic":[31],"class_list":["post-9638","post","type-post","status-publish","format-standard","hentry","category-article-summary","tag-vaccines","topic-vaccines-and-immunity"],"_links":{"self":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts\/9638","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/users\/8"}],"replies":[{"embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/comments?post=9638"}],"version-history":[{"count":1,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts\/9638\/revisions"}],"predecessor-version":[{"id":9639,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts\/9638\/revisions\/9639"}],"wp:attachment":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/media?parent=9638"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/categories?post=9638"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/tags?post=9638"},{"taxonomy":"topic","embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/topic?post=9638"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}